Press Releases | Page 16 of 42

Behind the Study: Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167

May 30, 2024

Dr. Benoit Chabot from Université de Sherbrooke discusses a research paper he co-authored that was published by Oncotarget, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167… read more

Figure 1: Molecular structure of Silibinin.

Oncotarget

The Importance of Integrated Therapies on Cancer: Silibinin, an Old and New Molecule

May 28, 2024

“This consideration could be the starting point to study whether Silibinin could contrast tumor progression, aging and inflammaging through molecular and cellular mechanisms [...].” BUFFALO, NY- May 28, 2024 –… read more

Table 8: Control data for transfection efficiency of uveal melanoma cells

Oncotarget

GZ17-6.02 Kills PDX Isolates of Uveal Melanoma

May 22, 2024

“The present studies demonstrated that GZ17-6.02 interacted with irreversible inhibitors of the EGF receptor and HER2 to kill uveal melanoma cells.” BUFFALO, NY- May 22, 2024 – A new research… read more

Figure 4: Depletion of DHX33 antagonizes GPS167-mediated cytotoxicity.

Oncotarget

Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167 via EMT and Antiviral Immune Response

May 20, 2024

“[...] we have characterized a pair of compounds that impact multiple processes that are relevant to cancer cell proliferation but also, and possibly more importantly, to metastasis [...].” BUFFALO, NY-… read more

Figure 1: Cyclin D1 protein expression by immunohistochemistry in histological sections.

Oncotarget

Cyclin D1 Expression in Penile Cancer

May 15, 2024

“Brazil holds the global record for penile cancer incidence.” BUFFALO, NY- May 15, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 14, 2024, entitled,… read more

Oncotarget

Oncotarget at SSP 46th Annual Meeting

May 13, 2024

Oncotarget is proud to participate at the Society for Scholarly Publishing (SSP) 46th Annual Meeting from May 29–31, 2024, in Boston, Massachusetts. BUFFALO, NY- May 13, 2024 – Impact Journals… read more

Figure 5: AI-generated PET results shown overlaid on CT.

Oncotarget

Deep Learning-based Whole-body Prostate-specific Membrane Antigen PET/CT Attenuation Correction

May 8, 2024

“We have developed a Pix-2-Pix GAN model to perform attenuation correction on whole-body PSMA [prostate-specific membrane antigen] PET images with 18F-DCFPyL.” BUFFALO, NY- May 8, 2024 – A new research… read more

Figure 4: The effect of SARS-CoV-2 spike on cell growth and death.

Oncotarget

Transfected SARS-CoV-2 Spike DNA Suppresses Cancer Cell Response to Chemotherapy

May 6, 2024

“Our findings have implications for the natural history of prolonged or repeated SARS-CoV-2 infection as well as design of anti-COVID-19 vaccines that are administered repeatedly as booster shots.” BUFFALO, NY-… read more

Oncotarget

Oncotarget Sponsors 19th International p53 Workshop in Italy

April 29, 2024

Oncotarget is a contributing sponsor at the 19th International p53 Workshop in Trieste, Italy, on May 13–16, 2024. BUFFALO, NY- April 29, 2024 – Oncotarget is a contributing sponsor at… read more

Figure 7: B-cell depletion of BTA106 in cynomolgus monkeys.

Oncotarget

Novel Therapeutic Bispecific Antibodies for B-cell Lymphoma

April 16, 2024

“Our results indicate that IgM-dependent bispecific antibodies are potent therapeutic agents for B-cell malignancies.” BUFFALO, NY- April 16, 2024 – A new research paper was published in Oncotarget's Volume 15… read more